Approach to Ventricular Arrhythmias in Heart Failure

Q: What is the clinical evidence from this study?

Study design: Review. Population: Ventricular arrhythmias in heart failure. Intervention: Early intervention (antiarrhythmic drugs, devices, catheter ablation).

Q: What does this research mean for the field?

Early intervention with antiarrhythmic drugs, cardiac implantable electronic devices, and catheter ablation reduces recurrent ventricular arrhythmias, device therapies, and mortality in heart failure patients. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Andrea Nichole Keithler; Klitos Konstantinidis

doi:10.1016/j.ccep.2026.06.011

August 11, 2026Cardiac Electrophysiology Clinics

Approach to Ventricular Arrhythmias in Heart Failure

View at Publisher

Ask AI

Bookmark

Share

Key result

Early multi-modality arrhythmia management reduces recurrent ventricular arrhythmias and mortality in heart failure.

Why the study?

Ventricular arrhythmia in heart failure patients causes significant morbidity and mortality despite modern therapies, necessitating effective management strategies.

Key Points

To synthesize current clinical management and procedural intervention strategies for ventricular arrhythmias in patients with heart failure.
Evaluated multimodal therapeutic approaches combining antiarrhythmic drug therapies, cardiac implantable electronic devices, and catheter ablation.
Assessed clinical approaches targeting adverse outcomes including electrical storm, cardiogenic shock, and sudden cardiac arrest.
Ventricular arrhythmias in heart failure frequently lead to recurrent electrical storms, device discharges, cardiogenic shock, and elevated mortality.
Early therapeutic intervention with procedural and pharmacological strategies qualitatively reduces arrhythmia recurrence, device shocks, and overall patient morbidity and mortality.

Structured PICO

P

Population

Patients with heart failure who have ventricular arrhythmia.

I

Intervention

Management strategies including antiarrhythmic drugs, cardiac implantable electronic devices, catheter ablation, and other adjunctive procedural management strategies.

O

Outcome

Recurrent ventricular arrhythmia, device therapies, and associated morbidity and mortality.

Implication

A comprehensive management approach utilizing antiarrhythmic drugs, devices, and ablation is essential to reduce morbidity and mortality associated with ventricular arrhythmias in heart failure patients.

Abstract

Ventricular arrhythmia remains a challenge in the heart failure population, resulting in significant morbidity and mortality despite modern heart failure therapies. Patients with heart failure who have ventricular arrhythmia experience morbidity related to electrical storm, cardiogenic shock, and device therapies and are at an increased risk for sudden cardiac arrest and death. The management of ventricular arrhythmia involves antiarrhythmic drugs, cardiac implantable electronic device, catheter ablation, and other adjunctive procedural management strategies. Early intervention can reduce recurrent ventricular arrhythmia, device therapies, and associated morbidity and mortality and is essential in the management of ventricular arrhythmia in the patient with heart failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keithler et al. (2026) conducted a review in Ventricular arrhythmias in heart failure. Early intervention (antiarrhythmic drugs, devices, catheter ablation) was evaluated. Early intervention using antiarrhythmic drugs, cardiac implantable electronic devices, and catheter ablation can reduce recurrent ventricular arrhythmia and mortality in heart failure.

synapsesocial.com/papers/6ad115aa00741cc3fba7d760 https://doi.org/10.1016/j.ccep.2026.06.011